SA517381665B1 - مستقبلات مولد ضد خيمري تستهدف مستقبل مقترن ببروتين واستخداماتها g - Google Patents
مستقبلات مولد ضد خيمري تستهدف مستقبل مقترن ببروتين واستخداماتها gInfo
- Publication number
- SA517381665B1 SA517381665B1 SA517381665A SA517381665A SA517381665B1 SA 517381665 B1 SA517381665 B1 SA 517381665B1 SA 517381665 A SA517381665 A SA 517381665A SA 517381665 A SA517381665 A SA 517381665A SA 517381665 B1 SA517381665 B1 SA 517381665B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- coupled receptor
- protein coupled
- chimeric antigen
- antigen receptors
- cars
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title abstract 5
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 title abstract 3
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 title abstract 3
- 230000008685 targeting Effects 0.000 title abstract 2
- 102100021197 G-protein coupled receptor family C group 5 member D Human genes 0.000 abstract 3
- 101001040713 Homo sapiens G-protein coupled receptor family C group 5 member D Proteins 0.000 abstract 2
- 101710174800 G-protein coupled receptor family C group 5 member D Proteins 0.000 abstract 1
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464469—Tumor associated carbohydrates
- A61K39/46447—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
Abstract
يتعلق الاختراع الحالي بتقديم في المادة الحالية التي تم الكشف عنها حالياً طرق وتركيبات لعلاج ورم نخاعي متعدد treating multiple myeloma. ويتعلق بمستقبلات مولد ضد خيمري chimeric antigen receptors (CARs) تستهدف على وجه التحديد مستقبل مقترن ببروتين G G-protein coupled receptor على سبيل المثال، عضو member D لمجموعة 5 من عائلة family C لمستقبل مقترن ببروتين G (GPRC5D))، وخلايا مخمدة مناعية immunoresponsive cells تشتمل على CARs المذكورة. تستهدف CARs التي تم الكشف عنها حالياً مستقبل مقترن ببروتين G (على سبيل المثال، GPRC5D) تتسم بخواص تنشيط مناعي محسنة، بما في ذلك تنشيط مضاد للورم anti-tumor activity.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462088286P | 2014-12-05 | 2014-12-05 | |
PCT/US2015/064102 WO2016090312A1 (en) | 2014-12-05 | 2015-12-04 | Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SA517381665B1 true SA517381665B1 (ar) | 2022-01-24 |
Family
ID=56092565
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SA517381665A SA517381665B1 (ar) | 2014-12-05 | 2017-06-05 | مستقبلات مولد ضد خيمري تستهدف مستقبل مقترن ببروتين واستخداماتها g |
Country Status (26)
Country | Link |
---|---|
US (4) | US10633426B2 (ar) |
EP (2) | EP3227339B1 (ar) |
JP (3) | JP6919091B2 (ar) |
KR (1) | KR102612367B1 (ar) |
CN (3) | CN113968912A (ar) |
AU (2) | AU2015357518B2 (ar) |
BR (1) | BR112017011920A2 (ar) |
CA (1) | CA2969864A1 (ar) |
CY (1) | CY1125008T1 (ar) |
DK (1) | DK3227339T3 (ar) |
ES (1) | ES2899779T3 (ar) |
HR (1) | HRP20211978T1 (ar) |
HU (1) | HUE057777T2 (ar) |
IL (2) | IL310130A (ar) |
LT (1) | LT3227339T (ar) |
MX (2) | MX2017007242A (ar) |
MY (1) | MY192065A (ar) |
PH (1) | PH12017501044A1 (ar) |
PL (1) | PL3227339T3 (ar) |
PT (1) | PT3227339T (ar) |
RS (1) | RS62870B1 (ar) |
RU (1) | RU2762359C2 (ar) |
SA (1) | SA517381665B1 (ar) |
SG (2) | SG11201704547RA (ar) |
SI (1) | SI3227339T1 (ar) |
WO (1) | WO2016090312A1 (ar) |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI3227339T1 (sl) | 2014-12-05 | 2022-02-28 | Memorial Sloan-Kettering Cancer Center | Himerni antigenski receptorji, ki ciljajo na receptor, povezan z G-proteinom, in njihova uporaba |
AU2015357535B2 (en) | 2014-12-05 | 2020-05-14 | Eureka Therapeutics, Inc. | Antibodies targeting G-protein coupled receptor and methods of use |
EP3466967A1 (en) | 2015-05-18 | 2019-04-10 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
CN109715668A (zh) | 2016-08-02 | 2019-05-03 | T细胞受体治疗公司 | 用于使用融合蛋白进行tcr重编程的组合物和方法 |
US10919966B2 (en) | 2016-08-05 | 2021-02-16 | Y-Biologics Inc. | Antibody to programmed death-ligand 1 (PD-L1) and use thereof |
PT3445787T (pt) | 2016-10-07 | 2021-03-15 | Tcr2 Therapeutics Inc | Composições e métodos para reprogramação de recetores de célula t com o uso de proteínas de fusão |
CN110177803A (zh) | 2016-11-22 | 2019-08-27 | T细胞受体治疗公司 | 用于使用融合蛋白进行tcr重新编程的组合物和方法 |
WO2018127916A1 (en) | 2017-01-05 | 2018-07-12 | Kahr Medical Ltd. | A pd1-cd70 fusion protein and methods of use thereof |
ES2916217T3 (es) | 2017-01-05 | 2022-06-29 | Kahr Medical Ltd | Una proteína de fusión SIRP1 ALPHA-41BBL y métodos de uso de la misma |
US11299530B2 (en) | 2017-01-05 | 2022-04-12 | Kahr Medical Ltd. | SIRP alpha-CD70 fusion protein and methods of use thereof |
HRP20230937T1 (hr) | 2017-01-05 | 2023-11-24 | Kahr Medical Ltd. | Pd1-41bbl fuzijski protein i metode korištenja istog |
CA3052938A1 (en) * | 2017-02-07 | 2018-08-16 | Daiichi Sankyo Company, Limited | Anti-gprc5d antibody and molecule comprising the antibody |
CA3059755A1 (en) | 2017-04-26 | 2018-11-01 | Eureka Therapeutics, Inc. | Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof |
CA3070575A1 (en) | 2017-08-09 | 2019-02-14 | Juno Therapeutics, Inc. | Methods and compositions for preparing genetically engineered cells |
WO2019032927A1 (en) | 2017-08-09 | 2019-02-14 | Juno Therapeutics, Inc. | METHODS FOR PRODUCING GENETICALLY MODIFIED CELL COMPOSITIONS AND COMPOSITIONS THEREOF |
WO2019051335A1 (en) | 2017-09-07 | 2019-03-14 | Juno Therapeutics, Inc. | METHODS OF IDENTIFYING CELLULAR CHARACTERISTICS RELATED TO RESPONSES ASSOCIATED WITH CELL THERAPY |
US11564946B2 (en) | 2017-11-01 | 2023-01-31 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
WO2019089858A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
EP3703688A2 (en) | 2017-11-01 | 2020-09-09 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for b-cell maturation antigen |
WO2019090003A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for b-cell maturation antigen (bcma) |
AU2018360801A1 (en) | 2017-11-01 | 2020-05-14 | Celgene Corporation | Process for producing a T cell composition |
CA3084514A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Process for generating therapeutic compositions of engineered cells |
AU2018367452A1 (en) | 2017-11-14 | 2020-06-11 | Memorial Sloan-Kettering Cancer Center | IL-36 secreting immunoresponsive cells and uses thereof |
EP3716980A1 (en) | 2017-12-01 | 2020-10-07 | Juno Therapeutics, Inc. | Methods for dosing and for modulation of genetically engineered cells |
WO2019113556A1 (en) | 2017-12-08 | 2019-06-13 | Juno Therapeutics, Inc. | Serum-free media formulation for culturing cells and methods of use thereof |
SG11202005272SA (en) | 2017-12-08 | 2020-07-29 | Juno Therapeutics Inc | Process for producing a composition of engineered t cells |
EP3720480A2 (en) | 2017-12-08 | 2020-10-14 | Juno Therapeutics, Inc. | Phenotypic markers for cell therapy and related methods |
US11827672B2 (en) | 2018-03-30 | 2023-11-28 | Eureka Therapeutics, Inc. | Constructs trageting CD22 and uses thereof |
EP3793606A4 (en) * | 2018-05-16 | 2022-08-31 | Janssen Biotech, Inc. | METHODS OF TREATMENT OF CANCER AND ENHANCEMENT OF THE EFFECTIVENESS OF T-CELL REFERRING THERAPEUTICS |
EP3833759A1 (en) | 2018-08-09 | 2021-06-16 | Juno Therapeutics, Inc. | Methods for assessing integrated nucleic acids |
BR112021002390A2 (pt) | 2018-08-09 | 2021-05-11 | Juno Therapeutics Inc | processos para gerar células modificadas e suas composições |
CN113454115A (zh) * | 2018-10-19 | 2021-09-28 | 纪念斯隆-凯特琳癌症中心 | 靶向唾液酸化路易斯a的嵌合抗原受体及其用途 |
BR112021008133A2 (pt) | 2018-10-31 | 2021-10-05 | Juno Therapeutics Gmbh | Métodos para seleção e estimulação de células e aparelhos para os mesmos |
JP2022506598A (ja) * | 2018-11-01 | 2022-01-17 | ジュノー セラピューティクス インコーポレイテッド | Gタンパク質共役受容体クラスcグループ5メンバーd(gprc5d)に特異的なキメラ抗原受容体 |
AU2019387497A1 (en) | 2018-11-30 | 2021-06-24 | Juno Therapeutics, Inc. | Methods for treatment using adoptive cell therapy |
JOP20210194A1 (ar) * | 2019-01-18 | 2023-01-30 | Janssen Biotech Inc | مستقبلات المستضدات الخيمرية لـ gprc5d وخلايا تعبر عنها |
WO2020223571A1 (en) | 2019-05-01 | 2020-11-05 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods |
KR20220016475A (ko) | 2019-05-01 | 2022-02-09 | 주노 쎄러퓨티크스 인코퍼레이티드 | 변형된 tgfbr2 유전자 좌에서 재조합 수용체를 발현하는 세포, 관련 폴리뉴클레오티드 및 방법 |
CA3142361A1 (en) | 2019-06-12 | 2020-12-17 | Juno Therapeutics, Inc. | Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein |
CN114555112A (zh) | 2019-08-22 | 2022-05-27 | 朱诺治疗学股份有限公司 | T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法 |
JP2023500318A (ja) | 2019-10-30 | 2023-01-05 | ジュノ セラピューティクス ゲーエムベーハー | 細胞選択および/または細胞刺激デバイスならびに使用方法 |
WO2021154887A1 (en) | 2020-01-28 | 2021-08-05 | Juno Therapeutics, Inc. | Methods for t cell transduction |
MX2022012685A (es) | 2020-04-10 | 2023-03-08 | Invivyd Inc | Compuestos específicos contra la proteína s de coronavirus y usos de los mismos. |
EP4150640A1 (en) | 2020-05-13 | 2023-03-22 | Juno Therapeutics, Inc. | Methods of identifying features associated with clinical response and uses thereof |
JP2023531531A (ja) | 2020-06-26 | 2023-07-24 | ジュノ セラピューティクス ゲーエムベーハー | 組換え受容体を条件付きで発現する操作されたt細胞、関連ポリヌクレオチド、および方法 |
CN116802203A (zh) | 2020-11-04 | 2023-09-22 | 朱诺治疗学股份有限公司 | 从经修饰的恒定cd3免疫球蛋白超家族链基因座表达嵌合受体的细胞、相关多核苷酸和方法 |
CN116635064A (zh) | 2020-12-18 | 2023-08-22 | 世纪治疗股份有限公司 | 具有适应性受体特异性的嵌合抗原受体系统 |
WO2022148370A1 (en) * | 2021-01-05 | 2022-07-14 | Lanova Medicines Development Co., Ltd. | Anti-gprc5d monoclonal antibodies and uses thereof |
WO2022187406A1 (en) | 2021-03-03 | 2022-09-09 | Juno Therapeutics, Inc. | Combination of a t cell therapy and a dgk inhibitor |
KR20230159851A (ko) | 2021-03-22 | 2023-11-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | 치료 세포 조성물의 효력을 결정하는 방법 |
CA3208944A1 (en) | 2021-03-22 | 2022-09-29 | Edith NALBANDIAN | Method to assess potency of viral vector particles |
IL307367A (en) * | 2021-04-07 | 2023-11-01 | Lg Chemical Ltd | GUCY2C binding polypeptide and uses thereof |
JP2024517863A (ja) | 2021-05-06 | 2024-04-23 | ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 細胞を刺激し、形質導入する方法 |
WO2022247756A1 (zh) * | 2021-05-23 | 2022-12-01 | 上海邦耀生物科技有限公司 | 靶向gprc5d的嵌合抗原受体及其用途 |
WO2023030272A1 (zh) | 2021-08-30 | 2023-03-09 | 原启生物科技(上海)有限责任公司 | 抗gprc5d抗原结合蛋白及其用途 |
US20230136301A1 (en) | 2021-11-03 | 2023-05-04 | Janssen Biotech, Inc. | Corticosteriod Reduction in Treatment with Anti-CD38 Antibody |
WO2023147515A1 (en) | 2022-01-28 | 2023-08-03 | Juno Therapeutics, Inc. | Methods of manufacturing cellular compositions |
WO2023213969A1 (en) | 2022-05-05 | 2023-11-09 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
WO2023225569A1 (en) | 2022-05-17 | 2023-11-23 | Umoja Biopharma, Inc. | Manufacturing viral particles |
WO2023230581A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Methods of manufacturing t cell therapies |
WO2023240282A1 (en) | 2022-06-10 | 2023-12-14 | Umoja Biopharma, Inc. | Engineered stem cells and uses thereof |
WO2023250122A1 (en) * | 2022-06-24 | 2023-12-28 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Molecules that bind to enpp1 polypeptides |
WO2024007020A1 (en) | 2022-06-30 | 2024-01-04 | Indapta Therapeutics, Inc. | Combination of engineered natural killer (nk) cells and antibody therapy and related methods |
WO2024031091A2 (en) | 2022-08-05 | 2024-02-08 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for gprc5d and bcma |
WO2024054944A1 (en) | 2022-09-08 | 2024-03-14 | Juno Therapeutics, Inc. | Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing |
WO2024097992A2 (en) | 2022-11-04 | 2024-05-10 | Umoja Biopharma, Inc. | Particles displaying adhesion-molecule fusions |
WO2024100604A1 (en) | 2022-11-09 | 2024-05-16 | Juno Therapeutics Gmbh | Methods for manufacturing engineered immune cells |
WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
CN117229407B (zh) * | 2023-11-14 | 2024-02-20 | 成都优赛诺生物科技有限公司 | 一种靶向gprc5d的单域抗体、嵌合抗原受体及其应用 |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
CA2407910C (en) | 2000-06-16 | 2013-03-12 | Steven M. Ruben | Antibodies that immunospecifically bind to blys |
CA2457496A1 (en) | 2001-08-20 | 2003-02-27 | Curagen Corporation | Gpcr-like retinoic acid-induced gene 1 protein and nucleic acid |
EP1468694A1 (en) * | 2001-12-27 | 2004-10-20 | Sumitomo Pharmaceuticals Company, Limited | Remedies for anorexia or lifestyle-related diseases and method of screening the same |
US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
US20040110139A1 (en) * | 2002-12-10 | 2004-06-10 | Isis Pharmaceuticals Inc. | Modulation of G protein-coupled receptor 3 expression |
EP1581171B1 (en) | 2002-12-20 | 2012-06-27 | Abbott Biotherapeutics Corp. | Antibodies against gpr64 and uses thereof |
WO2004072117A2 (en) | 2003-02-13 | 2004-08-26 | Pharmacia Corporation | Antibodies to c-met for the treatment of cancers |
WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
ES2537163T3 (es) * | 2003-12-10 | 2015-06-03 | E. R. Squibb & Sons, L.L.C. | Anticuerpos de IP-10 y sus usos |
US20050266008A1 (en) * | 2004-03-29 | 2005-12-01 | Medarex, Inc. | Human anti-IRTA-5 antibodies |
CA2658612C (en) | 2006-08-03 | 2015-11-17 | Astrazeneca Ab | Antibodies directed to .alpha.v.beta.6 and uses thereof |
US9512236B2 (en) | 2006-12-19 | 2016-12-06 | Ablynx N.V. | Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders |
WO2008121420A1 (en) | 2007-03-30 | 2008-10-09 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes |
EP2348052A3 (en) | 2007-09-17 | 2011-10-26 | The Regents of The University of California | Internalizing human monoclonal antibodies targeting prostate cancer cells in situ |
US7947807B2 (en) | 2007-10-15 | 2011-05-24 | The Board Of Trustees Of The Leland Stanford Junior University | Method for obtaining G protein-coupled receptor (GPCR) diffraction-quality crystals employing a monoclonal antibody that binds to the third intracellular loop (IL3) |
US7736648B2 (en) * | 2007-10-25 | 2010-06-15 | Trellis Bioscience, Inc. | Anti-RSV G protein antibodies |
ES2639857T3 (es) | 2008-02-11 | 2017-10-30 | Cure Tech Ltd. | Anticuerpos monoclonales para el tratamiento del tumor |
US9217032B2 (en) | 2010-01-08 | 2015-12-22 | Les Laboratoires Servier | Methods for treating colorectal cancer |
ES2739711T3 (es) | 2010-07-22 | 2020-02-03 | John W Schrader | Anticuerpo de protección cruzada contra la infección por el virus de la gripe |
BR122021026169B1 (pt) | 2010-12-09 | 2023-12-12 | The Trustees Of The University Of Pennsylvania | Uso de uma célula |
US9833476B2 (en) * | 2011-08-31 | 2017-12-05 | The Trustees Of Dartmouth College | NKP30 receptor targeted therapeutics |
CN103483452B (zh) * | 2012-06-12 | 2021-08-13 | 上海细胞治疗集团有限公司 | 双信号独立的嵌合抗原受体及其用途 |
WO2014087010A1 (en) | 2012-12-07 | 2014-06-12 | Ablynx N.V. | IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE |
JO3519B1 (ar) | 2013-01-25 | 2020-07-05 | Amgen Inc | تركيبات أجسام مضادة لأجل cdh19 و cd3 |
JP6450690B2 (ja) * | 2013-02-15 | 2019-01-09 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | キメラ抗原受容体及びその使用方法 |
EP3623380A1 (en) * | 2013-03-15 | 2020-03-18 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
EP3004337B1 (en) * | 2013-05-29 | 2017-08-02 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
MX2016017393A (es) | 2014-07-01 | 2017-09-05 | Pfizer | Diacuerpos heterodimericos biespecificos y sus usos. |
JP2017528433A (ja) | 2014-07-21 | 2017-09-28 | ノバルティス アーゲー | 低い免疫増強用量のmTOR阻害剤とCARの組み合わせ |
AU2015357535B2 (en) | 2014-12-05 | 2020-05-14 | Eureka Therapeutics, Inc. | Antibodies targeting G-protein coupled receptor and methods of use |
SI3227339T1 (sl) | 2014-12-05 | 2022-02-28 | Memorial Sloan-Kettering Cancer Center | Himerni antigenski receptorji, ki ciljajo na receptor, povezan z G-proteinom, in njihova uporaba |
EP3842450A1 (en) | 2015-10-23 | 2021-06-30 | Eureka Therapeutics, Inc. | Antibody/t-cell receptor chimeric constructs and uses thereof |
IL259747B (en) | 2015-12-04 | 2022-09-01 | Memorial Sloan Kettering Cancer Center | Antibodies against fcrl5 and methods of their use |
AU2017244108B2 (en) | 2016-03-29 | 2021-03-18 | University Of Southern California | Chimeric antigen receptors targeting cancer |
EP3436037A4 (en) | 2016-03-31 | 2019-12-04 | University of Southern California | HIGHLY SENSITIVE AND SPECIFIC LUCIFERASE-BASED REPORTER TEST FOR ANTIGEN DETECTION |
CN108239144B (zh) | 2018-01-26 | 2021-05-25 | 重庆精准生物技术有限公司 | 改造的铰链及其在构建car骨架中的应用 |
JP2022506598A (ja) | 2018-11-01 | 2022-01-17 | ジュノー セラピューティクス インコーポレイテッド | Gタンパク質共役受容体クラスcグループ5メンバーd(gprc5d)に特異的なキメラ抗原受容体 |
-
2015
- 2015-12-04 SI SI201531772T patent/SI3227339T1/sl unknown
- 2015-12-04 BR BR112017011920A patent/BR112017011920A2/pt active Search and Examination
- 2015-12-04 IL IL310130A patent/IL310130A/en unknown
- 2015-12-04 HU HUE15865633A patent/HUE057777T2/hu unknown
- 2015-12-04 KR KR1020177018389A patent/KR102612367B1/ko active IP Right Grant
- 2015-12-04 RS RS20211596A patent/RS62870B1/sr unknown
- 2015-12-04 JP JP2017529741A patent/JP6919091B2/ja active Active
- 2015-12-04 CN CN202111119531.9A patent/CN113968912A/zh active Pending
- 2015-12-04 WO PCT/US2015/064102 patent/WO2016090312A1/en active Application Filing
- 2015-12-04 SG SG11201704547RA patent/SG11201704547RA/en unknown
- 2015-12-04 PL PL15865633T patent/PL3227339T3/pl unknown
- 2015-12-04 EP EP15865633.0A patent/EP3227339B1/en active Active
- 2015-12-04 RU RU2017123551A patent/RU2762359C2/ru active
- 2015-12-04 LT LTEPPCT/US2015/064102T patent/LT3227339T/lt unknown
- 2015-12-04 IL IL252621A patent/IL252621B1/en unknown
- 2015-12-04 MY MYPI2017000855A patent/MY192065A/en unknown
- 2015-12-04 AU AU2015357518A patent/AU2015357518B2/en active Active
- 2015-12-04 EP EP21201788.3A patent/EP4015534A1/en active Pending
- 2015-12-04 DK DK15865633.0T patent/DK3227339T3/da active
- 2015-12-04 SG SG10202007326QA patent/SG10202007326QA/en unknown
- 2015-12-04 ES ES15865633T patent/ES2899779T3/es active Active
- 2015-12-04 CN CN202111126092.4A patent/CN113683711A/zh active Pending
- 2015-12-04 CA CA2969864A patent/CA2969864A1/en active Pending
- 2015-12-04 CN CN201580075557.4A patent/CN107428829B/zh active Active
- 2015-12-04 PT PT158656330T patent/PT3227339T/pt unknown
- 2015-12-04 MX MX2017007242A patent/MX2017007242A/es unknown
- 2015-12-04 HR HRP20211978TT patent/HRP20211978T1/hr unknown
-
2017
- 2017-06-05 SA SA517381665A patent/SA517381665B1/ar unknown
- 2017-06-05 US US15/613,800 patent/US10633426B2/en active Active
- 2017-06-05 PH PH12017501044A patent/PH12017501044A1/en unknown
- 2017-06-05 MX MX2021008798A patent/MX2021008798A/es unknown
-
2020
- 2020-02-21 US US16/798,151 patent/US10906956B2/en active Active
- 2020-02-21 US US16/798,104 patent/US11866478B2/en active Active
- 2020-02-21 US US16/798,059 patent/US11820806B2/en active Active
- 2020-11-30 JP JP2020198690A patent/JP2021040652A/ja not_active Withdrawn
-
2022
- 2022-01-06 AU AU2022200052A patent/AU2022200052A1/en active Pending
- 2022-02-07 CY CY20221100105T patent/CY1125008T1/el unknown
-
2023
- 2023-05-12 JP JP2023079310A patent/JP2023091037A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017501044A1 (en) | Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof | |
PH12017501041A1 (en) | Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof | |
SA517381666B1 (ar) | B مستقبلات مولد ضد خيمري تستهدف مولد ضد نضج الخلايا | |
CY1122831T1 (el) | Υποκινητης μνd χιμαιρικων αντιγονικων υποδοχεων | |
WO2015188141A3 (en) | Mesothelin-targeted chimeric antigen receptors and uses thereof | |
HK1252009A1 (zh) | 針對白細胞介素36受體(il-36r)的抗體 | |
SG11202000555UA (en) | Chimeric antigen receptors (cars), compositions and methods thereof | |
IL253049A0 (en) | chimeric antigen receptor-mab systems for sorting/depleting transgenic immune cells | |
EP3440191A4 (en) | CHIMERIC ANTIGEN RECEPTOR T CELL LYMPHOCYTE COMPOSITIONS | |
PH12017501039A1 (en) | Antibodies targeting g-protein coupled receptor and methods of use | |
EP3294764A4 (en) | Chimeric antigen receptor compositions | |
EP3474867A4 (en) | CHIMERIC ANTIGEN (CAR) RECEPTORS, COMPOSITIONS AND RELATED METHODS | |
PH12015502271A1 (en) | Compositions and methods for immunotherapy | |
EP4036109A3 (en) | Methods of making chimeric antigen receptor-expressing cells | |
MX2017003640A (es) | Receptores antigenicos quimericos. | |
WO2016014789A3 (en) | Bcma chimeric antigen receptors | |
EP3642344A4 (en) | PROCEDURES AND COMPOSITIONS FOR CANCER CELL TARGETING CHIMERIC ANTIGEN RECEPTORS |